收费全文 | 1895篇 |
免费 | 148篇 |
国内免费 | 67篇 |
耳鼻咽喉 | 14篇 |
儿科学 | 11篇 |
妇产科学 | 10篇 |
基础医学 | 112篇 |
口腔科学 | 46篇 |
临床医学 | 82篇 |
内科学 | 143篇 |
皮肤病学 | 25篇 |
神经病学 | 63篇 |
特种医学 | 57篇 |
外国民族医学 | 1篇 |
外科学 | 169篇 |
综合类 | 347篇 |
预防医学 | 28篇 |
眼科学 | 21篇 |
药学 | 209篇 |
中国医学 | 708篇 |
肿瘤学 | 64篇 |
2024年 | 13篇 |
2023年 | 48篇 |
2022年 | 54篇 |
2021年 | 88篇 |
2020年 | 79篇 |
2019年 | 115篇 |
2018年 | 123篇 |
2017年 | 100篇 |
2016年 | 54篇 |
2015年 | 56篇 |
2014年 | 113篇 |
2013年 | 109篇 |
2012年 | 112篇 |
2011年 | 135篇 |
2010年 | 102篇 |
2009年 | 68篇 |
2008年 | 54篇 |
2007年 | 68篇 |
2006年 | 65篇 |
2005年 | 60篇 |
2004年 | 72篇 |
2003年 | 67篇 |
2002年 | 59篇 |
2001年 | 49篇 |
2000年 | 48篇 |
1999年 | 31篇 |
1998年 | 24篇 |
1997年 | 20篇 |
1996年 | 11篇 |
1995年 | 26篇 |
1994年 | 6篇 |
1993年 | 11篇 |
1992年 | 10篇 |
1991年 | 11篇 |
1990年 | 10篇 |
1989年 | 3篇 |
1988年 | 6篇 |
1987年 | 6篇 |
1986年 | 1篇 |
1985年 | 3篇 |
1983年 | 7篇 |
1982年 | 4篇 |
1981年 | 5篇 |
1980年 | 2篇 |
1976年 | 1篇 |
1973年 | 1篇 |
Ethnopharmacological relevance
Pleurotus eryngii (DC. ex Fr.) Quel has been collected from the wild, cultivated and used in traditional medicines to treat various disorders and diseases since antiquity. In traditional Chinese medicine, the powdered fruiting bodies of Pleurotus eryngii were used for immunostimulation, skin-care, wound-healing, cancer and lumbago treatment. In the current study, we investigated the antiproliferative activity of Pleurotus eryngii powder on A549, BGC-823, HepG2 and HGC-27 cancer cells and its immunomodulating activity on macrophage, RAW 264.7 cells based on its active compound.Materials and methods
A novel bioactive protein (PEP) was extracted from Pleurotus eryngii fruiting bodies powder and purified on DEAE-52, CM-52 and Superdex 75 column chromatographies using an ÄKTA purifier. Its cytotoxicity on A549, BGC-823, HepG2, HGC-27 and RAW 267.4 cell lines was then evaluated using MTT, alamar blue (AB), trypan blue (TB), neutral red (NR), lactate dehydrogenase (LDH), Annexin V FITC/PI and morphological change assays. Moreover, lysosomal enzyme activity, pinocytosis, nitric oxide (NO) and hydrogen peroxide (H2O2) production assays were used to examine immunomostimulatory activity of PEP on RAW 267.4 cells.Results
Based on high performance gel permeation chromatography (HPGPC), Fourier transform infrared (FT-IR) and nuclear magnetic resonance (NMR) analyses, the isolated protein (PEP) had a molecular weight of 63 kDa, a secondary (α-helical) structure and was mainly composed of arginine, serine and glycine. PEP significantly (P<0.05) inhibited A549, BGC-823, HepG2 and HGC-27 tumor cells proliferation dose-dependently with an IC50 range of 36.5±0.84 to 229.0±1.24 µg/ml. Contrarily, PEP stimulated the proliferation of macrophages.Conclusion
Pleurotus eryngii fruiting bodies powder has a potential application as a natural antitumor agent with immunomodulatory activity, proposedly, by targeting the lysosomes of cancerous cells and stimulating macrophage-mediated immune responses. 相似文献Liu Wei Di Huang Wan (LDW), a well-known traditional Chinese medicine, is widely used for the treatment of various diseases in China. This study was designed to investigate the potential herb–drug interactions of LDW in healthy volunteers and attempted to ascertain whether the interaction might be affected by genotypes.
We assessed the effect of LDW on the activities of CYP2C19, CYP2D6 and CYP3A4 in 12 Chinese healthy subjects in a single-center, controlled, non-blinded, two-way crossover clinical trial. The subject pool consisted of six extensive metabolizers with CYP2C19*1/*1 and six poor metabolizers with CYP2C19*2/*2. Placebo or 4.8?g LDW (12 pills, 0.2?g/pill, twice daily) was given to each participant for 14 continuous days with a wash-out period of 2 weeks after an oral administration of 30?mg omeprazole, 30?mg dextromethorphan hydrobromide and 7.5?mg midazolam. The activities of CYP2C19, CYP2D6 and CYP3A4 were ascertained by their respective plasma or urinary metabolic ratios on day 14 post-treatment.
There is no difference in the activities of the three tested enzymes before or after a 14-day administration of LDW. LDW had no effect on the pharmacokinetic parameters of the substrates and their metabolites.
A 14-day administration of LDW did not affect the activities of CYP2C19, CYP2D6 and CYP3A4. LDW is unlikely to cause pharmacokinetic interaction when it is combined with other medications predominantly metabolized by these enzymes.